Profile
Jeff focuses on drug discovery and development opportunities across our portfolio.
Jeff brings 30 years of research and clinical experience including 18 years of experience leading drug discovery programs, technology development initiatives, preclinical development, and translational medicine.
Jeff has focused his career on breakthrough innovations which have included moving several first-in-class drugs into the clinic and developing novel technology platforms which integrate science, instruments, and informatics.
He holds several patents and he has published extensively in peer-reviewed journals.
Jeff obtained his M.D.
and Ph.D.
in Biochemistry from Stanford University School of Medicine, and he holds B.S.
degrees in Chemistry and Biology from Massachusetts Institute of Technology.
He completed residency training in Internal Medicine at Stanford and in Ophthalmology at Massachusetts Eye & Ear Infirmary and Harvard Medical School.
Jeffrey Finer active positions
| Companies | Position | Start |
|---|---|---|
Transcriptic, Inc.
 Transcriptic, Inc. Medical SpecialtiesHealth Technology Transcriptic, Inc. engages in the conversion of biology into an information technology, driven by data, and computation. It specializes in biology, automation, and software engineering. The company was founded by Max Joseph Hodak on February 14, 2012 and is headquartered in Menlo Park, CA. | Director/Board Member | 10/05/2018 |
Strateos, Inc.
 Strateos, Inc. Medical SpecialtiesHealth Technology Strateos engages in the automation of chemistry, biology, and tissue analysis into closed loop robotic laboratories that support drug discovery programs. The company is headquartered in the Menlo Park, CA. | Director/Board Member | 10/03/2022 |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/01/2016 |
Septerna, Inc.
 Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Founder | - |
Ambys Medicines, Inc.
 Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Ambys Medicines, Inc. develops regenerative medicine therapies for serious liver diseases. The company was founded by Martin Burke, Markus Grompe, Juan Carlos Izpisua Belmonte and Holger Willenbring and is headquartered in South San Francisco, CA. | Director/Board Member | 01/01/2019 |
Former positions of Jeffrey Finer
| Companies | Position | End |
|---|---|---|
| THERAVANCE BIOPHARMA, INC. | Private Equity Investor | 02/01/2016 |
| FIVE PRIME THERAPEUTICS, INC. | Private Equity Investor | 02/08/2011 |
| CYTOKINETICS, INCORPORATED | Private Equity Investor | 02/01/2007 |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Director/Board Member | - |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Jeffrey Finer
| Stanford University | Doctorate Degree |
| Massachusetts Institute of Technology | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| INNOVIVA, INC. | Health Technology |
| THERAVANCE BIOPHARMA, INC. | Health Technology |
| CYTOKINETICS, INCORPORATED | Health Technology |
| Private companies | 7 |
|---|---|
Transcriptic, Inc.
Transcriptic, Inc. Medical SpecialtiesHealth Technology Transcriptic, Inc. engages in the conversion of biology into an information technology, driven by data, and computation. It specializes in biology, automation, and software engineering. The company was founded by Max Joseph Hodak on February 14, 2012 and is headquartered in Menlo Park, CA. | Health Technology |
Strateos, Inc.
Strateos, Inc. Medical SpecialtiesHealth Technology Strateos engages in the automation of chemistry, biology, and tissue analysis into closed loop robotic laboratories that support drug discovery programs. The company is headquartered in the Menlo Park, CA. | Health Technology |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Commercial Services |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Health Technology |
Ambys Medicines, Inc.
Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Ambys Medicines, Inc. develops regenerative medicine therapies for serious liver diseases. The company was founded by Martin Burke, Markus Grompe, Juan Carlos Izpisua Belmonte and Holger Willenbring and is headquartered in South San Francisco, CA. | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
- Stock Market
- Insiders
- Jeffrey Finer
